Breaking News
January 22, 2019 - Amgen And UCB Receive Positive Vote From FDA Advisory Committee In Favor Of Approval For Evenity (romosozumab)
January 22, 2019 - Does being bilingual make children more focused? Study says no
January 22, 2019 - Study reveals new genes and biological pathways linked to osteoarthritis
January 22, 2019 - FSU study provides better understanding of spinal cord injuries
January 22, 2019 - Delaying bath for newborn babies increases breastfeeding rates, finds study
January 21, 2019 - Many parents still try non-evidence-based cold prevention methods for children
January 21, 2019 - High Levels of Activity, Motor Ability Linked to Better Cognition
January 21, 2019 - Killer blows? Knockout study of pair of mouse MicroRNA provides cancer insight
January 21, 2019 - Buffalo researchers receive grant to quicken development of generic equivalents of contraceptives
January 21, 2019 - One-third of pregnant women do not believe cannabis is harmful to their fetus
January 21, 2019 - Fiderstat could be used as chemopreventative drug for intestinal cancers caused by APC gene mutations
January 21, 2019 - Modifying healthcare delivery practices may improve discussions between youth and healthcare providers
January 21, 2019 - UNIST researcher named as recipient of Merck’s 2018 Life Science Awards
January 21, 2019 - How Getting a Flu Shot Could Save Your Life
January 21, 2019 - Surgical adhesions can be treated, prevented in mice
January 21, 2019 - Increased physician-targeted marketing associated with higher opioid overdose deaths
January 21, 2019 - Researchers uncover specific microbial signatures of intestinal disease
January 21, 2019 - Simple blood test reliably detects signs of Alzheimer’s damage before symptoms
January 21, 2019 - Study to investigate new targeted oral treatments for severe asthma
January 21, 2019 - Plan Your Plate | NIH News in Health
January 21, 2019 - Fecal occult blood test may improve CRC outcomes in some
January 21, 2019 - Blood test detects Alzheimer’s disease years before symptoms develop
January 21, 2019 - Mount Sinai joins with Paradigm and ReqMed to repurpose drug for treatment of MPS
January 21, 2019 - FDA Advisory Committee Votes on Zynquista (sotagliflozin) as Treatment for Adults with Type 1 Diabetes
January 21, 2019 - The causes and complications of snoring
January 21, 2019 - Placenta adapts and compensates when pregnant mothers have poor diets or low oxygen
January 21, 2019 - New implant could restore the transmission of electrical signals in injured central nervous system
January 21, 2019 - Rapid-acting fentanyl test strips found to be effective at reducing overdose risk
January 21, 2019 - Coronary Artery Calcium May Help Predict CVD in South Asians
January 21, 2019 - The mystery of the super-ager
January 21, 2019 - Scientists develop smart microrobots that can change shape depending on their surroundings
January 21, 2019 - Keep Moving to Keep Brain Sharp in Old Age
January 21, 2019 - Despite progress, gay fathers and their children still structurally stigmatized
January 21, 2019 - New drug for treating liver parasites in vivax malaria
January 21, 2019 - Merck recognized with 2018 Life Science Industry Award for best use of social media
January 21, 2019 - Coeur Wallis equips the canton of Valais with 260 SCHILLER defibrillators
January 21, 2019 - Scientists propose quick and pain-free method for diagnosing kidney cancer
January 21, 2019 - Signs of memory loss could point to hearing issues
January 21, 2019 - HeartFlow Analysis shows highest diagnostic performance for detecting coronary artery disease
January 21, 2019 - How Much Caffeine is Too Much?
January 21, 2019 - Take a timeout before you force your child to apologize
January 21, 2019 - Scientists design two AI algorithms to improve early detection of cognitive impairment
January 21, 2019 - Novel therapy for children with chronic hormone deficiency provides lifeline for parents
January 21, 2019 - Bioethicists call for oversight of poorly regulated, consumer-grade neurotechnology products
January 21, 2019 - Study shows hereditary hemochromatosis behind many cancers and joint diseases
January 21, 2019 - Short bouts of stairclimbing throughout the day can improve cardiovascular health
January 20, 2019 - Liver Transplant Survival May Improve With Race Matching
January 20, 2019 - Study implicates hyperactive immune system in aging brain disorders
January 20, 2019 - Cancer Diagnosis May Quadruple Suicide Risk
January 20, 2019 - Parkinson’s disease experts devise a roadmap
January 20, 2019 - Research brings new hope to treating degenerative brain diseases
January 20, 2019 - Scientists pinpoint a set of molecules that wire the body weight center of the brain
January 20, 2019 - Researchers get close to developing elusive blood test for Alzheimer’s disease
January 20, 2019 - UCLA researchers demonstrate new technique to develop cancer-fighting T cells
January 20, 2019 - Researchers discover how cancer cells avoid genetic meltdown
January 20, 2019 - Exercise makes even the ‘still overweight’ healthier: study
January 20, 2019 - University of Utah to establish first-of-its-kind dark sky studies minor in the US
January 20, 2019 - School-based nutritional programs reduce student obesity
January 20, 2019 - Improved maternity care practices in the southern U.S. reduce racial inequities in breastfeeding
January 20, 2019 - New enzyme biomarker test indicates diseases and bacterial contamination
January 20, 2019 - Republican and Democratic governors have different visions to transform health care, say researchers
January 20, 2019 - Researchers discover that spin flips happen in only half a picosecond in the course of a chemical reaction
January 20, 2019 - Suicide Risk Up More Than Fourfold for Cancer Patients
January 20, 2019 - Doctors find 122 nails in Ethiopian’s stomach
January 20, 2019 - UV disinfection technology eliminates up to 97.7% of pathogens in operating rooms
January 20, 2019 - Researchers discover mechanism which drives leukemia cell growth
January 20, 2019 - AHA: Infection as a Baby Led to Heart Valve Surgery for Teen
January 20, 2019 - Injection improves vision in a form of childhood blindness
January 20, 2019 - Multiple sclerosis therapies delay progression of disability
January 20, 2019 - New study finds infrequent helmet use among bike share riders
January 20, 2019 - Clearing up information about corneal dystrophies
January 20, 2019 - Researchers describe new behavior in energy metabolism that refutes existing evidence
January 20, 2019 - New study takes first step toward treating endometriosis
January 20, 2019 - Researchers find how GREB1 gene promotes resistance to prostate cancer treatments
January 20, 2019 - Replacing Sitting Time With Activity Lowers Mortality Risk
January 20, 2019 - A simple, inexpensive intervention makes birth safer for moms and babies in parts of Africa
January 19, 2019 - New anti-inflammatory compound acts as ‘surge protector’ to reduce cancer growth
January 19, 2019 - Significant flaws found in recently released forensic software
January 19, 2019 - New Leash on Life? Staying Slim Keeps Pooches Happy, Healthy
January 19, 2019 - Men and women remember pain differently
New drug for migraine in the pipeline

New drug for migraine in the pipeline

image_pdfDownload PDFimage_print

According to a pilot study results released yesterday (17th of April 2018), a new drug may help provide relief to people with migraine that is unsuccessfully treated with the currently available drugs.

Researchers have developed Erenumab, which belongs to a human monoclonal antibody class of drugs that can block calcitonin gene-related peptide (CGRP). This CGRP is a molecule that can transmit the signals of pain during an attack of migraine. According to experts, blocking CGRP can prevent the onset of a migraine attack before it even starts. Researchers have found that a long lasting injection of the new drug can prevent the onset of the migraine attacks by blocking the CGRP.

Migraine. Image Credit: svershinsky / Shutterstock

Migraine. Image Credit: svershinsky / Shutterstock

Migraine affects over thirty-seven million Americans according to the American Headache Society. Around 4 million Americans suffer from chronic migraine which means they have attacks of debilitating headaches for at least 10 to 14 days in a month. Treatment includes over the counter pain medications such as ibuprofen and also stronger medications such as sumatriptan and ergotamine. Migraine is essentially caused by dilatation of the blood vessels around the brain that leads to intense headache, nausea and dizziness. Sumatriptan and ergotamine help to constrict these blood vessels and thus ease the pain. These drugs however may not be effective in all people with migraine.

Lead author of the study Dr. Peter Goadsby, professor of neurology at Kings College London, UK and University of California, San Francisco said that this is the first time a drug can effectively prevent the attacks of migraine. He said that this drug will change the treatment for people who do not respond to the traditional treatments available for migraine.

The study involved adults with chronic migraine who had four to fourteen attacks of migraine per month. Those with over 15 attacks per month and who have failed to respond to treatment with drugs such as topiramate, propranolol and amitriptyline were included in this study. The new drug was used among the participants.

This study included 246 participants who were given 140 mg of erenumab or a placebo once in a month for three months. Of these 39 percent had earlier been treated unsuccessfully with two other anti-migraine medications, 38 percent were earlier treated with three other medications and 23 percent were unsuccessful with even four medications. At baseline the participants had an average of nine migraine headaches per month and had to use a drug to curb an acute attack at least five times a month.

The results revealed that in over a third of the study participants the monthly migraine attacks were reduced by more than half. Patients experienced a three times more chance of reduced migraine days by 50 percent after being treated with the new drug for three months compared to those who were treated using a placebo. The number of days that the patients needed to stop the attacks of migraine were also significantly reduced in these patients. Number of days with headaches also reduced substantially. None of the patients who were put on the new drug Erenumab had to discontinue the drug because they experienced side effects. The study was supported by Novartis Pharma AG.

The makers hope that this new drug would get a green light from the Food and Drug Administration this year. The cost of the drug is estimated to be around $10,000 annually at present. The study results would be presented at the American Academy of Neurology’s 70th Annual Meeting in Los Angeles, between April 21st and 27th, 2018.

Source:

https://www.aan.com/PressRoom/Home/PressRelease/1641

Tagged with:

About author

Related Articles